Neuregulin 1 (NRG1) modulates oocyte nuclear maturation during IVM and improves post-IVF embryo development.


Journal

Theriogenology
ISSN: 1879-3231
Titre abrégé: Theriogenology
Pays: United States
ID NLM: 0421510

Informations de publication

Date de publication:
01 Jan 2023
Historique:
received: 14 09 2022
revised: 31 10 2022
accepted: 31 10 2022
pubmed: 12 11 2022
medline: 23 11 2022
entrez: 11 11 2022
Statut: ppublish

Résumé

Oocyte in vitro maturation (IVM) is still a major challenge in human and animal assisted reproduction. Gradual instead of abrupt activation of the ovulatory cascade during IVM has been proposed to enhance nuclear-cytoplasmic synchrony and cumulus-oocyte communication, thus favoring oocyte developmental competence. Herein, we assessed the effects of neuregulin 1 (NRG1), an EGF-like factor that modulates EGFR signaling, on oocyte nuclear maturation dynamics, cumulus expansion and expression of mRNAs regulating these processes during IVM, as well as on post-IVF embryo development following AREG-stimulated IVM in cattle. In experiment 1, cumulus-oocyte complexes (COCs) were subjected to IVM with graded doses of NRG1 (1, 10 or 100 ng/mL) for 6, 9, 12, 20, and 24 h, after which oocyte nuclear status and cumulus mRNA expression were assessed. At 6 h of IVM, NRG1 at 1 ng/mL significantly decreased the percentage of GVBD (germinal vesicle breakdown) oocytes without altering later meiotic dynamics or the percentage of oocytes achieving meiosis II. In experiment 2, adding NRG1 (1 ng/mL) to the IVM medium did not affect cumulus expansion but increased the percentage of expanded and hatched blastocysts, and blastocyst total cell number following IVF/IVC. NRG1 decreased EGFR mRNA abundance while increasing NPR2 and PTX3 mRNA levels at 9 h, and TNFAIP6 mRNA abundance at 20 h of IVM. This is the first study that reports the modulatory effect of NGR1 during oocyte maturation in a mono-ovulatory species and demonstrates that this action may be applied during IVM to improve post-IVF embryo development.

Identifiants

pubmed: 36368115
pii: S0093-691X(22)00455-1
doi: 10.1016/j.theriogenology.2022.10.041
pii:
doi:

Substances chimiques

Neuregulin-1 0
RNA, Messenger 0
ErbB Receptors EC 2.7.10.1
NRG1 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

209-216

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no conflicts of interest.

Auteurs

Thaisy Tino Dellaqua (TT)

Department of Structural and Functional Biology, Institute of Biosciences, Sao Paulo State University, Botucatu, Sao Paulo, Brazil.

Renan Aparecido Vígaro (RA)

Department of Structural and Functional Biology, Institute of Biosciences, Sao Paulo State University, Botucatu, Sao Paulo, Brazil.

Ludimila Cardoso Zoccal Janini (LCZ)

Department of Veterinary Surgery and Animal Reproduction, School of Veterinary Medicine and Animal Science, Sao Paulo State University, Botucatu, Sao Paulo, Brazil.

Mariabeatrice Dal Canto (M)

Biogenesi, Reproductive Medicine Centre, Monza, Italy.

Mario Mignini Renzini (MM)

Biogenesi, Reproductive Medicine Centre, Monza, Italy.

Valentina Lodde (V)

Reproductive and Developmental Biology Laboratory, Department of Veterinary Medicine and Animal Science, University of Milan, Milan, Italy.

Alberto Maria Luciano (AM)

Reproductive and Developmental Biology Laboratory, Department of Veterinary Medicine and Animal Science, University of Milan, Milan, Italy.

Jose Buratini (J)

Department of Structural and Functional Biology, Institute of Biosciences, Sao Paulo State University, Botucatu, Sao Paulo, Brazil; Biogenesi, Reproductive Medicine Centre, Monza, Italy. Electronic address: j.buratini@unesp.br.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH